ADHD at 39th ECNP Congress
3 sessions on adhd · October 10–13, 2026, Munich, Germany. Compare adhd at other meetings →
Sunday, October 11
Symposium
S05 – Biomarker-based prediction and stratification in ADHD – where do we stand?
Cristine Marie Yde Ohki · Carmen Schiweck · Barbara Franke · Marta Ribasés
Microbiota metabolites, inflammation, epigenetics, and polygenic risk as candidate stratification biomarkers in ADHD.
Inflammation & Immunopsychiatry · Pharmacogenomics & Precision Psychiatry
Tuesday, October 13
Symposium
S16 – Cutting edge neuromodulation methods in brain disorders: methods, mechanisms and personalised targeting
Yvan Vachez · Katya Rubia · Odile van den Heuvel · Christine Reif-Leonhard
DBS, trigeminal nerve stimulation in ADHD, rTMS-augmented exposure therapy for OCD, and implantable VNS for difficult-to-treat depression.
Neuromodulation (ECT, TMS) · OCD & Related Disorders · Treatment-Resistant Depression
Lecture
E07 – Long-term effects of ADHD medication: new evidence from real-world data
Real-world evidence on long-term academic outcomes and the safety of methylphenidate in children.
Other topics at this meeting
Neuroscience & Mechanisms 23Drug Pipeline & Clinical Trials 8Digital Psychiatry & AI 7Pharmacogenomics & Precision Psychiatry 7Inflammation & Immunopsychiatry 6Schizophrenia & Psychosis 6Child & Adolescent 5Depression 5Autism & Neurodevelopmental Disorders 4Neuromodulation (ECT, TMS) 4OCD & Related Disorders 4Practice, Policy & Workforce 3